Related Experiment Video
Updated: May 22, 2026
Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer
Published on: March 17, 2016
Research resource: Transcriptional profiling in a cellular model of breast cancer reveals functional and mechanistic
Suzanne E Wardell1, Dmitri Kazmin, Donald P McDonnell
1Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Box 3813, Durham, North Carolina 27710, USA.
Abstract:
Exploitation of the relationship between estrogen receptor (ER) structure and activity has led to the development of 1) selective ER modulators (SERM), compounds whose relative agonist/antagonist activities differ between target tissues; 2) selective ER degraders (SERD), compounds that induce a conformational change in the receptor that targets it for proteasomal degradation; and 3) tissue-selective estrogen complexes (TSEC), drugs in which a SERM and an ER agonist are combined to yield a blended activity that results in distinct clinical profiles. In this study, we have performed a comprehensive head-to-head analysis of the transcriptional activity of these different classes of ERM in a cellular model of breast cancer. Not surprisingly, these studies highlighted important functional differences and similarities among the existing SERM, selective ER degraders, and TSEC. Of particular importance was the identification of genes that were regulated by various TSEC combinations but not by an estrogen or SERM alone. Cumulatively, the findings of this analysis are informative with respect to the mechanisms by which ER is engaged by different enhancers/promoters and highlights how promoter context influences the pharmacological activity of ER ligands.
Insights
Selective estrogen receptor modulators (SERMs), degraders (SERDs), and complexes (TSEC) show distinct transcriptional activities in breast cancer cells. TSEC revealed unique gene regulation not seen with estrogen or SERMs alone.
Area of Science:
- Endocrinology
- Molecular Biology
- Pharmacology
Background:
- Estrogen receptor (ER) targeted therapies include selective ER modulators (SERMs), selective ER degraders (SERDs), and tissue-selective estrogen complexes (TSEC).
- These agents exploit ER structure-activity relationships to achieve tissue-specific effects.
Purpose of the Study:
- To conduct a comprehensive head-to-head analysis of the transcriptional activity of SERMs, SERDs, and TSEC.
- To identify functional differences and similarities among these ER-targeting drug classes in a breast cancer model.
Main Methods:
- Utilized a cellular model of breast cancer.
- Performed a comparative analysis of transcriptional activity for different ER-targeting agents.
Main Results:
- Highlighted significant functional differences and similarities among SERMs, SERDs, and TSEC.
- Identified specific genes regulated by TSEC combinations that were unresponsive to estrogen or SERM treatment alone.
Conclusions:
- Findings provide insights into ER engagement mechanisms by various enhancers/promoters.
- Demonstrated how promoter context influences the pharmacological activity of ER ligands.
